Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

3.380 +0.310 (+10.10%)
Streaming Delayed Price Updated: 10:47 AM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prelude Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
PRLD Stock Earnings: Prelude Therapeutics Misses EPS for Q2 2024 ↗
PRLD stock results show that Prelude Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
From Prelude Therapeutics, Incorporated
Via GlobeNewswire
News headline image
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22 ↗
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024. 
Via Talk Markets
News headline image
Morgan Stanley Downgrades Prelude Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Prelude Therapeutics ↗
 
Via Benzinga
News headline image
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
PRLD Stock Earnings: Prelude Therapeutics Beats EPS for Q1 2024 ↗
PRLD stock results show that Prelude Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitor 
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
AI Meets Biotech: 3 Top Stocks Transforming Medical Science ↗
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Prelude Therapeutics Announces $25 Million Private Placement
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader 
From Prelude Therapeutics, Inc.; AbCellera
Via GlobeNewswire
News headline image
Best Buy To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  Wednesday's session saw 150 companies set new 52-week lows. 
Via Benzinga
News headline image
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 27 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During Thursday, 56 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  Friday's session saw 59 companies set new 52-week lows. 
Via Benzinga
News headline image
Prelude Therapeutics To Participate in Jefferies Healthcare Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.